BioCentury
ARTICLE | Politics & Policy

Experimental GBM vaccine available under U.S. right-to-try program

October 3, 2019 8:28 PM UTC
Updated on Oct 3, 2019 at 11:47 PM UTC

ERC is making its experimental glioblastoma multiforme vaccine Gliovac available to patients under a program based on the federal right-to-try law.

The company is the first to develop an experimental therapy program to treat patients under RTT since it was signed into law in May 2018, according to Arizona-based think tank Goldwater Institute, which drafted model RTT legislation (see “Trump Signs Right-to-Try Into Law”)...

BCIQ Company Profiles

ERC-Belgium S.A.